Fiche du document
1 février 2022
- doi: 10.1186/s40478-022-01313-y
- issn: 2051-5960
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1186/s40478-022-01313-y
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35105380
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2051-5960
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_C808421C91844
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Neutrophilic leucocytes Polynuclear leucocytes Polymorphonuclear leucocytes Apoplexy Cerebrovascular disorders Cerebrovascular syndrome Brain--Blood-vessels--Diseases Cerebral circulation disorders Stroke CVA (Disease) Cerebral vascular accident Cerebrovascular accidentCiter ce document
A. Genchi et al., « Neutrophils predominate the immune signature of cerebral thrombi in COVID-19 stroke patients. », Serveur académique Lausannois, ID : 10.1186/s40478-022-01313-y
Métriques
Partage / Export
Résumé
Coronavirus disease 2019 (COVID-19) is associated with an increased risk of thrombotic events. Ischemic stroke in COVID-19 patients entails high severity and mortality rates. Here we aimed to analyze cerebral thrombi of COVID-19 patients with large vessel occlusion (LVO) acute ischemic stroke to expose molecular evidence for SARS-CoV-2 in the thrombus and to unravel any peculiar immune-thrombotic features. We conducted a systematic pathological analysis of cerebral thrombi retrieved by endovascular thrombectomy in patients with LVO stroke infected with COVID-19 (n = 7 patients) and non-covid LVO controls (n = 23). In thrombi of COVID-19 patients, the SARS-CoV-2 docking receptor ACE2 was mainly expressed in monocytes/macrophages and showed higher expression levels compared to controls. Using polymerase chain reaction and sequencing, we detected SARS-CoV-2 Clade20A, in the thrombus of one COVID-19 patient. Comparing thrombus composition of COVID-19 and control patients, we noted no overt differences in terms of red blood cells, fibrin, neutrophil extracellular traps (NETs), von Willebrand Factor (vWF), platelets and complement complex C5b-9. However, thrombi of COVID-19 patients showed increased neutrophil density (MPO + cells) and a three-fold higher Neutrophil-to-Lymphocyte Ratio (tNLR). In the ROC analysis both neutrophils and tNLR had a good discriminative ability to differentiate thrombi of COVID-19 patients from controls. In summary, cerebral thrombi of COVID-19 patients can harbor SARS-CoV2 and are characterized by an increased neutrophil number and tNLR and higher ACE2 expression. These findings suggest neutrophils as the possible culprit in COVID-19-related thrombosis.
